Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FUPOCAN
Taipei, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Fupocan Biomedical is a clinical-stage biotechnology company focused on the development of innovative small molecule therapeutics for the treatment of solid tumors. The company's lead candidate, FPC-001, is a first-in-class DNA polymerase inhibitor designed to disrupt cancer cell replication by targeting DNA polymerases alpha, delta, and epsilon. Fupocan aims to address unmet medical needs in oncology, particularly for patients with gastrointestinal cancers such as colorectal and pancreatic cancer. The company is currently advancing its pipeline through early-phase clinical trials to evaluate safety and preliminary efficacy.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on FUPOCAN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FUPOCAN.